Cargando…
The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
Multiple myeloma (MM) is an incurable haematological malignancy which relies heavily on bone marrow biopsies for disease monitoring and prediction of treatment response. In recent years, liquid biopsy derived cell-free DNA (cfDNA) has emerged as alternative for invasive biopsies. This pilot study ai...
Autores principales: | Marivel, A-M Joëlle, Ma, Yafeng, Becker, Therese M., Verma, Anvita, Trieu, Steven, Roberts, Tara L., Ling, Silvia C.W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613886/ https://www.ncbi.nlm.nih.gov/pubmed/37908506 http://dx.doi.org/10.1016/j.lrr.2023.100393 |
Ejemplares similares
-
Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019) -
Impact of mosaicism ratio on positive predictive value of cfDNA screening
por: Rafalko, Jill M., et al.
Publicado: (2020) -
Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019) -
Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges
por: García-Pardo, Miguel, et al.
Publicado: (2022) -
cfDNA screening and diagnosis of monogenic disorders – where are we heading?
por: Chiu, Eunice Ka Long, et al.
Publicado: (2018)